Show simple item record

dc.contributor.authorGammon, David C.
dc.contributor.authorLizotte, Margaret W.
dc.date2022-08-11T08:08:06.000
dc.date.accessioned2022-08-23T15:42:29Z
dc.date.available2022-08-23T15:42:29Z
dc.date.issued2004-07-27
dc.date.submitted2010-03-10
dc.identifier.citation<p>J Infus Nurs. 2004 Jul-Aug;27(4):251-3.</p>
dc.identifier.issn1533-1458 (Linking)
dc.identifier.pmid15273632
dc.identifier.urihttp://hdl.handle.net/20.500.14038/26858
dc.description.abstractThis study challenges the current practice of administering paclitaxel for a variety of malignancies over 3 hours and documents the safety and cost-effectiveness of 1-hour administration in the outpatient setting. The authors investigated opportunities to save nursing time and costs in a cancer clinic without compromising patient safety. These savings are referred to as "opportunity-cost savings" that enable the clinic to schedule more patients during the time normally required to administer a 3-hour paclitaxel dose. Over a 2-year period, the authors were able to document significant time savings with no increase in adverse drug reactions.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15273632&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://insights.ovid.com/pubmed?pmid=15273632
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCost-Benefit Analysis
dc.subjectFemale
dc.subject*Health Care Costs
dc.subjectHumans
dc.subjectInfusions, Intravenous
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasms
dc.subjectPaclitaxel
dc.subject*Safety
dc.subjectTime Factors
dc.subjectPharmacy and Pharmaceutical Sciences
dc.titleSafety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies
dc.typeJournal Article
dc.source.journaltitleJournal of infusion nursing : the official publication of the Infusion Nurses Society
dc.source.volume27
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/clinpharm_pp/5
dc.identifier.contextkey1212964
html.description.abstract<p>This study challenges the current practice of administering paclitaxel for a variety of malignancies over 3 hours and documents the safety and cost-effectiveness of 1-hour administration in the outpatient setting. The authors investigated opportunities to save nursing time and costs in a cancer clinic without compromising patient safety. These savings are referred to as "opportunity-cost savings" that enable the clinic to schedule more patients during the time normally required to administer a 3-hour paclitaxel dose. Over a 2-year period, the authors were able to document significant time savings with no increase in adverse drug reactions.</p>
dc.identifier.submissionpathclinpharm_pp/5
dc.contributor.departmentDepartment of Pharmacy
dc.source.pages251-3


This item appears in the following Collection(s)

Show simple item record